InnoCare orelabrutinib hits Phase IIb endpoints in SLE study
InnoCare Pharma has presented Phase IIb data showing its BTK inhibitor orelabrutinib met both primary and secondary endpoints in patients with moderate-to-severe systemic lupus erythematosus, with results disclosed at the EULAR 2026 European Congress of Rheumatology in London.
The randomised, double-blind, placebo-controlled study enrolled 187 patients across three arms: orelabrutinib 75 mg once daily, orelabrutinib 50 mg once daily, and placebo. The primary endpoint — SLE Response Index-4 (SRI-4) response rate at week 48 — was achieved by 57.1% of patients in the 75 mg arm compared with 34.4% in the placebo group (p = 0.01). Secondary endpoints, measured by SRI-6 and BICLA response rates at week 48, were also met at statistical significance (p < 0.05) for the 75 mg cohort.
Steroid reduction signals clinical relevance
An important secondary finding was the impact on corticosteroid use, a clinically meaningful outcome in a disease where long-term steroid exposure is associated with significant comorbidity. Some 71.1% of patients in the 75 mg group achieved steroid reduction to 7.5 mg or less, compared with 43.6% in the placebo group. Mean cumulative corticosteroid exposure was reduced by 301 mg over 48 weeks against placebo. No new safety signals were identified, and the overall tolerability profile was described as consistent with earlier studies.
InnoCare is positioning orelabrutinib as the first BTK inhibitor to demonstrate significant efficacy at Phase II level for SLE, a claim the company makes in the release. While the Phase IIb data are encouraging, the field will await the ongoing registrational Phase III trial — for which InnoCare says patient enrolment is being accelerated — before drawing firm conclusions about regulatory candidacy.
Competitive landscape and regulatory read-across
SLE is a notoriously difficult indication with a long history of Phase III failures, and the BTK inhibitor class has attracted increasing interest as a mechanism capable of targeting B-cell and myeloid pathways implicated in lupus pathogenesis. Several large pharmaceutical companies have evaluated BTK inhibition in autoimmune settings, though validated Phase II SLE data in this class have been limited prior to this readout.
The regulatory path for SLE therapies runs through the FDA and EMA under relatively established frameworks, with SRI-4 and BICLA now the accepted primary endpoints in pivotal trials — a point InnoCare's study design explicitly addresses. The company's dual-listed status on the Hong Kong Stock Exchange and Shanghai Stock Exchange means any regulatory filing strategy will likely involve China's National Medical Products Administration as well as Western agencies, adding complexity but also potential for a large initial commercial market.
The broader autoimmune landscape is expanding: several oral small-molecule candidates, including TYK2 and JAK inhibitors, are approved or in late-stage development for adjacent indications such as lupus nephritis and myositis. If orelabrutinib's Phase III programme replicates the Phase IIb SRI-4 and steroid-sparing signals, it could represent a meaningful addition to a treatment toolkit that currently relies heavily on hydroxychloroquine, belimumab, and anifrolumab. Investors will monitor enrolment pace and the anticipated readout timeline as the next material catalysts.